Karyopharm Therapeutics Inc. has announced the granting of 666 restricted stock units (RSUs) to two newly-hired employees as of June 30, 2025. These RSUs were awarded under the company's 2022 Inducement Stock Incentive Plan, in line with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over three years, with one-third vesting on each anniversary of the grant date, contingent upon the employees' continued service. Additionally, the RSUs will become fully exercisable if the employee's employment is terminated for "good reason" or without "cause" within a year of a "change in control event."
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。